| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/21/2023 | 566.67% | JonesTrading | → $8 | Initiates Coverage On | → Buy |
| 05/17/2023 | 483.33% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 05/17/2023 | 816.67% | Chardan Capital | → $11 | Reiterates | Buy → Buy |
| 02/09/2023 | 483.33% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/09/2023 | 816.67% | Chardan Capital | → $11 | Reiterates | → Buy |
| 10/17/2022 | 483.33% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 09/08/2022 | 816.67% | Chardan Capital | → $11 | Initiates Coverage On | → Buy |
What is the target price for Purple Biotech (PPBT)?
The latest price target for Purple Biotech (NASDAQ: PPBT) was reported by JonesTrading on July 21, 2023. The analyst firm set a price target for $8.00 expecting PPBT to rise to within 12 months (a possible 566.67% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Purple Biotech (PPBT)?
The latest analyst rating for Purple Biotech (NASDAQ: PPBT) was provided by JonesTrading, and Purple Biotech initiated their buy rating.
When is the next analyst rating going to be posted or updated for Purple Biotech (PPBT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Purple Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Purple Biotech was filed on July 21, 2023 so you should expect the next rating to be made available sometime around July 21, 2024.
Is the Analyst Rating Purple Biotech (PPBT) correct?
While ratings are subjective and will change, the latest Purple Biotech (PPBT) rating was a initiated with a price target of $0.00 to $8.00. The current price Purple Biotech (PPBT) is trading at is $1.20, which is within the analyst's predicted range.
